CAS: 7789-47-1; Mercury Dibromide

上下游产品

mercury(II) telluride bromine3',5'-di-O-benzyl-4'-thiothymidine mercury(I) bromide methylmercury(II) bromide bromo(phenyl)mercury

📜氢溴酸 反应生成 溴化汞
参考文献:Tomashik,V. N.;Sava,A. A.,Xim. Metody Obrab. Poverxnostej Neorgan. Mater.: Tez. Dokl. 3 Bcec. Semin+
标题:Tomashik,V. N.;Sava,A. A.,Xim. Metody Obrab. Poverxnostej Neorgan. Mater.: Tez. Dokl. 3 Bcec. Semin+

专利信息

专利号:US-7615169-B2
优先权日:2004-09-20
标题 :Method for synthesis of colloidal nanoparticles
发明人：STROUSE GEOFFREY FIELDING; GERBEC JEFFREY A; MAGANA DONNY
权利人:UNIV CALIFORNIA
摘要:A method for synthesis of high quality colloidal nanoparticles using comprises a high heating rate process. Irradiation of single mode, high power, microwave is a particularly well suited technique to realize high quality semiconductor nanoparticles. The use of microwave radiation effectively automates the synthesis, and more importantly, permits the use of a continuous flow microwave reactor for commercial preparation of the high quality colloidal nanoparticles.

专利号:US-7927516-B2
优先权日:2004-09-20
标题 :Method for synthesis of colloidal nanoparticles
发明人：STROUSE GEOFFREY F; GERBEC JEFFREY A; MAGANA DONNY
权利人:UNIV CALIFORNIA
摘要:A method for synthesis of high quality colloidal nanoparticles using comprises a high heating rate process. Irradiation of single mode, high power, microwave is a particularly well suited technique to realize high quality semiconductor nanoparticles. The use of microwave radiation effectively automates the synthesis, and more importantly, permits the use of a continuous flow microwave reactor for commercial preparation of the high quality colloidal nanoparticles.

专利号:US-4794176-A
优先权日:1981-06-26
标 题 :Synthesis of tumor antigenic determinant
发明人：LEMIEUX RAYMOND U; RATCLIFFE ROBERT M; BAKER DONALD A
权利人:CHEMBIOMED
摘要:Processes are provided for the synthesis of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-α-D-galactopyranoside containing an α-O-glycosidically linked bridging arm O--(CH 2 ) n COR. The determinant is coupled to carrier molecules to form artifical T-antigens, and to insoluble supports to form T-immunoadsorbents. The artificial T-antigen is shown to elicit a delayed type hypersensitivity reaction as a diagnostic for the presence of cancer in humans.

专利号:US-4767845-A
优先权日:1980-07-10
标题 :Synthesis of tumor antigenic determinant
发明人：LEMIEUX RAYMOND U; RATCLIFFE ROBERT M; BAKER DONALD A
权利人:CHEMBIOMED LTD
摘要:Processes are provided for the synthesis of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(β-D-galactopyranosyl)-α-D-galactopyranoside containing an α-O-glycosidically linked bridging arm O--(CH 2 ) n COR. The determinant is coupled to carrier molecules to form artificial T-antigens, and to insoluble supports to form T-immunoadsorbents. The artifical T-antigen is shown to elicit a delayed type hypersensitivity reaction as a diagnostic for the presence of cancer in humans.

专利号:US-4818816-A
优先权日:1981-04-28
标 题:Process for the organic synthesis of oligosaccharides and derivatives thereof
发明人：PETITOU MAURICE; JACQUINET JEAN-CLAUDE; SINAY PIERRE; CHOAY JEAN; LORMEAU JEAN-CLAUDE; NASSR MAHMOUD
权利人:CHOAY SA
摘要:The invention relates to a process for the organic synthesis of oligosaccharides constituting or comprising fragments of acid mucopolysaccharides comprising the reaction of two compounds constituted or terminated by units of glucosamine structure and of uronic acid structure respectively, said units being specifically substituted. This process particularly enables valuable anticoagulant drugs to be obtained.

专利号:US-4943630-A
优先权日:1982-10-27
标题 :Method for carrying out the organic synthesis of oligosaccharides containing galactosamine-uronic acid patterns, new oligosaccharides obtained and biological applications thereof
发明人：JACQUINET JEAN-CLAUDE; PETITOU MAURICE; SINAY PIERRE; CHOAY JEAN
权利人:CHOAY SA
摘要:Process for the organic synthesis of oligosaccharides forming or corresponding to fragments of acid mucopolysaccharides wherein two compounds comprised of or terminated respectively by patterns of galactosamine structure and patterns of uronic acid structure. Said patterns are specifically substituted. Said process results in oligosaccharides usable particularly in therapy.